Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
Date:11/1/2011

compounds, and the potential therapeutic and commercial potential of LX1031, LX1032, LX1033, LX2931, and LX4211. This press release also contains forward-looking statements relating to Lexicon's partnership discussions with third parties with respect to the development and commercialization of LX1032.  In addition, this press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031, LX1032, LX1033, LX2931, and LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, including with respect to LX1032, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whethe
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
2. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
3. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
4. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
5. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
6. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
7. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
8. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
9. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
10. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
11. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015 The Haselmeier Group has ... Gert Weber has been nominated by the ... Chief Executive Officer (CEO) of the Haselmeier Group. ... 2015. Mr. Weber brings more than 20 years of ... filled various executive management positions, the last being Managing ...
(Date:6/30/2015)... Calif. , June 30, 2015  The MEDevice ... consecutive year, is an event dedicated to bringing medtech ... hottest issues and topics affecting the industry today. This ... address the challenges and opportunities facing today,s medtech professional ... information and to register for MEDevice San Diego, please ...
(Date:6/30/2015)...  IGI Laboratories, Inc. (NYSE MKT: IG), a ... company, today announced it has submitted its fifth abbreviated ... Drug Administration (FDA) of 2015, which brings the Company,s ... FDA to twenty-seven. Jason Grenfell-Gardner , ... our current pipeline of twenty-seven submissions, exclusive of our ...
Breaking Medicine Technology:Haselmeier Group Announces the Extension and Reorganization of its Executive Board 2MEDevice San Diego 2015 Attracts High-Tech Medical Industry 2IGI Laboratories, Inc. Announces Fifth ANDA Submission Of 2015 2
... Technologies, Incorporated (IDEV), an emerging leader in the development and ... named Christopher M. Owens its President and Chief Executive Officer, ... of results-based leadership and is the right person to take ... Anderson. "Chris has a clear vision and strategy of how ...
... Romeo and Juliette Laser Hair Removal on ... in New York City to own the newly introduced Elite ... manufacturer of laser and light-based aesthetic treatment systems. ... technology, is a highly versatile laser aesthetic workstation that combines ...
Cached Medicine Technology:IDEV Technologies Names Christopher M. Owens President, Chief Executive Officer 2Romeo and Juliette Laser Hair Removal Is First Center in New York City to Own Cynosure's New Elite MPX(TM) Laser System 2
(Date:7/1/2015)... ... 01, 2015 , ... B. E. Smith, the only full-service ... a national chief executive officer recruitment for Citizens Medical Center in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/1/2015)... ... ... Incentivizing the use of generic drugs has been an easy way for ... 90% off the prices for the brand-name products. But now that generics are experiencing ... of these high-cost generic drugs. The July issue of Atlantic Information Services, Inc.’s (AIS) ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... global distribution and marketing of a number of nutritional and beauty products, announced ... the 2015 ECRM Diet, Vitamin & Sports Nutrition conference in Tampa, Florida. This ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... across platforms and devices, today announced the opening of a new operational office ... and support that enables collaboration across all lines of business for organizations throughout ...
(Date:7/1/2015)... ... 2015 , ... First Harvest Financial , a leading ... legal cannabis startups can interact with corporate executives, serial entrepreneurs and ... looking to strategically enter and capitalize on growing and creating therapeutic cannabis based ...
Breaking Medicine News(10 mins):Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 3Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 2Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 3Health News:NPI Executives Report Great Success at ECRM Conference 2Health News:AvePoint Opens Office in Zurich to Meet Increasing Market Demand for Enterprise Collaboration Solutions in Switzerland 2Health News:AvePoint Opens Office in Zurich to Meet Increasing Market Demand for Enterprise Collaboration Solutions in Switzerland 3Health News:First Harvest Financial Partners in Launch of Legal Medical Cannabis Documentary Initiative 2Health News:First Harvest Financial Partners in Launch of Legal Medical Cannabis Documentary Initiative 3
... affecting one in 100 people worldwide. Most cases aren,t detected ... as a teenager or adult. By that time, the disease ... to treat. In a paper published recently online by ... University of North Carolina at Chapel Hill and Columbia University ...
... usually about how much of something is due to our ... research just published in the academic journal Addiction ... who smoke, drink, or use drugs, for two related reasons. ... substance use is also predisposed to choose friends who smoke, ...
... Tiger Woods ... is a procedure Dr. Manish Gupta offers at Specialty Orthopedic Center of Boca Raton, FL. ... (PRWEB) June 21, 2010 ... the focus was not on his golf game or his recent lack of. The central ...
... ... ... resident Roger Sencer was driving home from work in May 2009 when he couldn’t remember important ... him to Huntington Hospital. The news was not good: the emergency physician ran tests and ...
... and the University of Ferrara in Italy have collaborated to ... pain without causing many of the side effects of current ... of cancer patients experience pain in the final year of ... use of drugs like morphine produces side effects such as ...
... Multiple sclerosis patients who directly confronted the stress of the ... to cope with the situation by focusing on feelings. This ... researchers of the University of Haifa, the Technion-Israel Institute of ... for multiple sclerosis to date, it is important to uncover ...
Cached Medicine News:Health News:Brain signs of schizophrenia found in babies 2Health News:New research shows peer drug use may increase an individual's genetic tendency to use drugs 2Health News:Tiger Takes Another Shot: PRP Injections Put On the Spot 2Health News:3-D Brain Navigation, Minimally Invasive Surgery Combine to Help Neurosurgeon Remove Tennis Ball-Sized Tumor 2Health News:3-D Brain Navigation, Minimally Invasive Surgery Combine to Help Neurosurgeon Remove Tennis Ball-Sized Tumor 3Health News:New drugs to relieve cancer pain 2Health News:Can multiple sclerosis attacks be minimized in a war zone? 2
Tungsten Carbide wire twister....
Designed to have a shock-absorbing force, providing less bounce or wasted force....
Osteophyte periosteal elevator for bone removing....
Angled ring curette....
Medicine Products: